CervoMed Inc. CRVO 深 沪
等待开盘 03-27 09:30:00 美东时间
3.92
-0.120
-2.97%
华盛通- 最 高5.12
- 今 开4.04
- 成交量 2.91万股
- 最 低 3.76
- 昨 收 4.04
- 总市值 0
- 52周最高 13.13
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 3.58
- 委 比 -99.25%
- 总股本 --
- 历史最高 26.3789
- 量 比 0.63
- 振 幅 33.66%
- 历史最低 1.80
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alpha Buying: Managing Biotech Risk With Insider Clues
Biotech stocks have a way of making smart people do dumb things. It starts inno...
01-16 00:32
450亿机器人概念股发布业绩预告|创业板盘后公告集锦
（来源：创业板观察） 今日聚焦 【金力永磁：前三季度净利同比预增157%-179% 具身机器人电机转子及磁材产品均有小批量交付】 金力永磁(300748.SZ...
2025-10-09 21:06
科创板晚报|晶合集成筹划发行H股并在香港联交所上市 百奥泰重组抗VEGF人源化单克隆抗体注射液获批临床试验
登录新浪财经APP 搜索【信披】查看更多考评等级 转自：财联社 《科创板日报》8月1日讯今日科创板晚报主要内容包括：上海：至2025年底新建...
2025-08-01 20:55
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
CervoMed has hired Dr. Marco Verwijs as Executive Vice President, Technical Operations to strengthen CMC leadership and prepare for the Phase 3 trial of neflamapimod in DLB in mid-2026.
2025-06-10 12:00
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Paymentus Holdings, Inc. (NYSE:PAY) rose sharply in today's pre-marke...
2025-03-11 18:55
CervoMed Announces Results From Extension Phase Of Phase 2b Clinical Study Of Neflamapimod
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in
2025-03-11 04:06
Chardan Capital Initiates Coverage On CervoMed with Buy Rating, Announces Price Target of $55
Chardan Capital analyst Daniil Gataulin initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target of $55.
2024-09-19 02:38
